Table 1 Number of implanted specimens and engrafted xenograft tumor models.

From: Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers

Primary Site

Patients

No-XG (%)

XG_P0 (%)

Stable XG (%)

Pancreas

199

81 (41)

118 (59)

99 (50)

PDAC*

169

64 (38)

105 (62)

89 (52)

IPMN**

15

10 (66)

5(33)

3 (20)

Mucinous adenocarcinoma

4

1 (25)

3 (75)

3 (75)

Squamous carcinoma

1

0 (0)

1 (100)

1 (100)

Undifferentiated carcinoma

2

0 (0)

2 (100)

1 (50)

Solid pseudopapillary carcinoma

2

2 (100)

0 (0)

0 (0)

Acinar cell carcinoma

1

0 (0)

1 (100)

1 (100)

Neuroendocrine carcinoma

5

4 (80)

1 (20)

1 (20)

Biliary duct

48

31 (64)

17 (35)

8 (17)

Ampullary-duodenum

29

4 (14)

25 (86)

20 (69)

Total

276

116 (42)

160(58)

127(46)

  1. Patient-derived tumor models (XG) after initial passage (P0) in mice and serial passages for at least three passages to evaluate stable xenograft propagation (SXG). PDAC pancreatic ductal adenocarcinoma; IPMN intraductal papillary mucinous neoplasm.
  2. *A subset of PDAC were ascites specimens; 6/21 had initial engraftment and also formed SXG models.
  3. **15 IPMNs included eight with invasive adenocarcinoma; XG_P0 IMPN cases were associated with invasive adenocarcinoma (4/5) and one with focal invasion; Stable XG IPMN cases were associated with invasive adenocarcinoma (n = 2), and focal invasion (n = 1).
Back to article page